ZyVersa Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for patients with renal and inflammatory diseases addressing significant unmet medical needs. The company leverages proprietary platforms to advance its pipeline, including Cholesterol Efflux Mediator VAR 200, an injectable formulation of 2-hydroxypropyl-beta-cyclodextrin (2HPβCD) in Phase 2a clinical trials targeting diabetic kidney disease (DKD), focal segmental glomerulosclerosis (FSGS), and Alport syndrome by removing excess cholesterol and lipids from the kidney's filtration system (glomeruli podocytes) to protect structure, reduce proteinuria, and preserve renal function; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody in preclinical development that inhibits intracellular ASC to block inflammasome formation and ASC specks to attenuate systemic inflammation, with lead indication in obesity and associated metabolic complications, and potential applications in central nervous system disorders such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis, as well as non-CNS conditions including atherosclerosis, acute respiratory distress syndrome, pancreatic cancer, and Huntington's disease. Founded in 2014 and headquartered in Weston, Florida, ZyVersa operates primarily in the United States with a focus on global markets for its therapies and maintains license agreements with L&F Research LLC and InflamaCORE, LLC for its proprietary technologies. In June 2025, the company entered a share purchase agreement with Williamsburg Venture Holdings for up to $10 million in flexible equity financing to support clinical development of VAR 200, followed by a $2 million warrant inducement transaction in July 2025, providing total access to $12 million in capital for research and development initiatives. Amid these financings, ZyVersa initiated an open-label Phase 2a pilot trial for VAR 200 in DKD patients in mid-June 2025, with preliminary data expected in Q4 2025 and final results in H1 2026, alongside providing FDA-authorized emergency compassionate use of VAR 200 for a patient with rare ApoCII amyloidosis at the University of Miami Miller School of Medicine; the company also plans preclinical initiation for IC 100 in Q3 2025 and reported delisting from Nasdaq with continued trading on OTCQB.
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 65.4% – Still a Buy?
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)
ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200
ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status